127 related articles for article (PubMed ID: 17952764)
1. Nanotherapeutics for enhancing thermal therapy of cancer.
Visaria R; Bischof JC; Loren M; Williams B; Ebbini E; Paciotti G; Griffin R
Int J Hyperthermia; 2007 Sep; 23(6):501-11. PubMed ID: 17952764
[TBL] [Abstract][Full Text] [Related]
2. Enhancement of tumor thermal therapy using gold nanoparticle-assisted tumor necrosis factor-alpha delivery.
Visaria RK; Griffin RJ; Williams BW; Ebbini ES; Paciotti GF; Song CW; Bischof JC
Mol Cancer Ther; 2006 Apr; 5(4):1014-20. PubMed ID: 16648573
[TBL] [Abstract][Full Text] [Related]
3. Combination of Gold Nanoparticle-Conjugated Tumor Necrosis Factor-α and Radiation Therapy Results in a Synergistic Antitumor Response in Murine Carcinoma Models.
Koonce NA; Quick CM; Hardee ME; Jamshidi-Parsian A; Dent JA; Paciotti GF; Nedosekin D; Dings RP; Griffin RJ
Int J Radiat Oncol Biol Phys; 2015 Nov; 93(3):588-96. PubMed ID: 26461001
[TBL] [Abstract][Full Text] [Related]
4. Nanoparticle enhanced thermal therapies.
Shenoi MM; Anderson J; Bischof JC
Annu Int Conf IEEE Eng Med Biol Soc; 2009; 2009():1979-82. PubMed ID: 19964027
[TBL] [Abstract][Full Text] [Related]
5. Novel Dual-Action Targeted Nanomedicine in Mice With Metastatic Thyroid Cancer and Pancreatic Neuroendocrine Tumors.
Nilubol N; Yuan Z; Paciotti GF; Tamarkin L; Sanchez C; Gaskins K; Freedman EM; Cao S; Zhao J; Kingston DGI; Libutti SK; Kebebew E
J Natl Cancer Inst; 2018 Sep; 110(9):1019-1029. PubMed ID: 29481652
[TBL] [Abstract][Full Text] [Related]
6. Optimizing the factors which modify thermal enhancement of melphalan in a spontaneous murine tumor.
Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH
Cancer Chemother Pharmacol; 2006 Dec; 58(6):719-24. PubMed ID: 16614851
[TBL] [Abstract][Full Text] [Related]
7. Effect of timing, dose and interstitial versus nanoparticle delivery of tumor necrosis factor alpha in combinatorial adjuvant cryosurgery treatment of ELT-3 uterine fibroid tumor.
Jiang J; Bischof J
Cryo Letters; 2010; 31(1):50-62. PubMed ID: 20309509
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of antitumor activity of tumor necrosis factor alpha with hyperthermia in a tumor necrosis factor alpha-resistant tumor.
Srinivasan JM; Fajardo LF; Hahn GM
J Natl Cancer Inst; 1990 Dec; 82(24):1904-10. PubMed ID: 2250311
[TBL] [Abstract][Full Text] [Related]
9. Significance of additive heat effect in the therapeutic gain factor in combined hyperthermia and radiotherapy: murine tumor response and foot reaction.
Sougawa M; Urano M
Int J Radiat Oncol Biol Phys; 1991 Nov; 21(6):1561-8. PubMed ID: 1938566
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and hyperthermia: factors that modify thermal enhancement.
Mohamed F; Stuart OA; Glehen O; Urano M; Sugarbaker PH
J Surg Oncol; 2004 Oct; 88(1):14-20. PubMed ID: 15384091
[TBL] [Abstract][Full Text] [Related]
11. Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy.
Shenoi MM; Iltis I; Choi J; Koonce NA; Metzger GJ; Griffin RJ; Bischof JC
Mol Pharm; 2013 May; 10(5):1683-94. PubMed ID: 23544801
[TBL] [Abstract][Full Text] [Related]
12. [The synergistic effect of human recombinant TNF in combination with hyperthermia].
Watanabe N; Umeno H; Sone H; Neda H; Yamauchi N; Umetsu T; Niitsu Y; Urushizaki I
Nihon Gan Chiryo Gakkai Shi; 1987 Apr; 22(3):632-7. PubMed ID: 3655489
[No Abstract] [Full Text] [Related]
13. Therapeutic efficacy of long duration-low temperature whole body hyperthermia when combined with tumor necrosis factor and carboplatin in rats.
Sakaguchi Y; Makino M; Kaneko T; Stephens LC; Strebel FR; Danhauser LL; Jenkins GN; Bull JM
Cancer Res; 1994 Apr; 54(8):2223-7. PubMed ID: 8174130
[TBL] [Abstract][Full Text] [Related]
14. TNF-alpha-based accentuation in cryoinjury--dose, delivery, and response.
Goel R; Swanlund D; Coad J; Paciotti GF; Bischof JC
Mol Cancer Ther; 2007 Jul; 6(7):2039-47. PubMed ID: 17620433
[TBL] [Abstract][Full Text] [Related]
15. Increased therapeutic efficacy induced by tumor necrosis factor alpha combined with platinum complexes and whole-body hyperthermia in rats.
Ohno S; Strebel FR; Stephens LC; Siddik ZH; Makino M; Klostergaard J; Tomasovic SP; Khokhar AR; Bull JM
Cancer Res; 1992 Aug; 52(15):4096-101. PubMed ID: 1638521
[TBL] [Abstract][Full Text] [Related]
16. Tumor necrosis factor alpha mediates the antitumor effect of combined interleukin-2 and whole body hyperthermia.
Fritz KL; Koziol S; Fabian DF; Lefor AT
J Surg Res; 1996 Jan; 60(1):55-60. PubMed ID: 8592432
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution of TNF-alpha-coated gold nanoparticles in an in vivo model system.
Goel R; Shah N; Visaria R; Paciotti GF; Bischof JC
Nanomedicine (Lond); 2009 Jun; 4(4):401-10. PubMed ID: 19505243
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic interactions of tumor necrosis factor, melphalan and 41.8 degrees C hyperthermia.
Robins HI; d'Oleire F; Kutz M; Bird A; Schmitt-Tiggelaar CL; Cohen JD; Spriggs DR
Cancer Lett; 1995 Feb; 89(1):55-62. PubMed ID: 7882302
[TBL] [Abstract][Full Text] [Related]
19. Synergistic antitumor effect of recombinant adeno-associated virus-mediated pigment epithelium-derived factor with hyperthermia on solid tumor.
Wu Q; He S; Wei X; Shao B; Luo S; Guo F; Zhang H; Wang Y; Gong C; Yang L
Hum Gene Ther; 2014 Sep; 25(9):811-23. PubMed ID: 25003563
[TBL] [Abstract][Full Text] [Related]
20. Thermal enhancement of both tumour necrosis factor alpha-induced systemic toxicity and tumour cure in rats.
van der Zee J; van den Aardweg GJ; van Rhoon GC; van den Berg AP; de Wit R
Br J Cancer; 1995 Jun; 71(6):1158-62. PubMed ID: 7779705
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
